MONECO Advisors’s Matinas BioPharma MTNB Stock Holding History

MONECO Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-600	Closed	-$19K	–	276
2022 Q3	$19K	Hold	600	–	–	0.01%	244
2022 Q2	$24K	Hold	600	–	–	0.01%	246
2022 Q1	$24K	Hold	600	–	–	0.01%	245
2021 Q4	$22K	Hold	600	–	–	0.01%	245
2021 Q3	$39K	Sell	600 -400	-40%	-$17.3K	0.02%	254
2021 Q2	$39K	Hold	1,000	–	–	0.02%	219
2021 Q1	$53K	Hold	1,000	–	–	0.03%	215
2020 Q4	$81K	Sell	1,000 -200	-17%	-$9.26K	0.04%	183
2020 Q3	$46K	Hold	1,200	–	–	0.03%	159
2020 Q2	$46K	Buy	+1,200	New	+$46K	0.04%	138

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MONECO Advisors's MTNB Position: Q4 2022 in Review

MONECO Advisors sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 600 shares — an estimated $19K sold.

MONECO Advisors first reported a position in MTNB in Q2 2020 and held it in 10 quarters. The position peaked at $81K in Q4 2020. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

MONECO Advisors reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
MONECO Advisors sold 600 Matinas BioPharma shares in Q4 2022, an estimated $19K.
MONECO Advisors first reported a position in Matinas BioPharma in Q2 2020 and held it in 10 quarters.
MONECO Advisors's Matinas BioPharma position peaked at $81K in Q4 2020.
57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on MONECO Advisors's 13F filing for Q4 2022, filed 30 Jan 2023.